General Information of Drug (ID: DMEJYV4)

Drug Name
(S)-4-(Ethylsulfonyl)benzoylalanine Drug Info
Synonyms S-ESBA
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Preclinical [1]
Schizophrenia 6A20 Preclinical [1]
Cross-matching ID
TTD Drug ID
DMEJYV4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
US10065972, Example 560 DM9QCTJ N. A. N. A. Patented [3]
US8933095, 1 DMG3T7E N. A. N. A. Patented [4]
US10065972, Example 281 DMBWJK4 N. A. N. A. Patented [3]
US8933095, 16 DMRN5F4 N. A. N. A. Patented [4]
US10065972, Example 396 DMT8WVZ N. A. N. A. Patented [3]
US8933095, 18 DMOZ4FS N. A. N. A. Patented [5]
US8933095, 14 DMZUNJ4 N. A. N. A. Patented [5]
PF-04859989 DM3U2S5 Cognitive impairment 6D71 Preclinical [6]
BFF-122 DM6BGJ9 Cognitive impairment 6D71 Preclinical [1]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Kynurenine oxoglutarate transaminase II (AADAT) TTT3IXG AADAT_HUMAN Inhibitor [2]

References

1 Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
2 Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009 Mar 3;159(1):196-203.
3 Bicyclic or tricyclic heterocyclic compound. US10065972.
4 KAT II inhibitors. US8933095.
5 KAT II inhibitors. US8598200.
6 Investigating KYNA production and kynurenergic manipulation on acute mouse brain slice preparations. Brain Res Bull. 2019 Mar;146:185-191.